Computerised System Validation Plan

A pharmacovigilance computerised system should not enter regulated use on the strength of testing alone. Before testing begins, the organisation needs a reasoned explanation of what the system is expected to do, which parts of that use matter most, what evidence will be relied upon, who is accountable for each decision, and how the conclusion of fitness for purpose will be maintained after go-live. The Computerised System Validation Plan, often shortened to CSV Plan or simply Validation Plan, is a practical way of organising that explanation.

The plan is not the validation itself. It is the governance document that defines the validation strategy. Requirements, risk assessments, supplier assessments, specifications, test evidence, deviations, traceability records and release decisions then implement that strategy. A strong plan therefore connects the regulated pharmacovigilance process to the evidence that will ultimately support release and continued operation.

This distinction is particularly important in pharmacovigilance because the same technology may support very different levels of regulatory consequence. A global safety database may calculate reporting due dates and generate regulatory messages; a signal platform may transform data used in safety evaluation; a document repository may preserve controlled procedures; and a reporting warehouse may feed aggregate analyses. Validation planning should reflect how the organisation actually relies on each system rather than applying an identical template to every application.

Purpose and Scope

The purpose of a Validation Plan is to define, before substantial assurance work is performed, how the organisation intends to demonstrate that a particular computerised system is fit for its intended pharmacovigilance use. It should make the validation argument understandable in advance: what is in scope, which risks matter, which evidence will be generated or reused, how acceptance will be judged, and how responsibilities are divided.

A useful plan answers six connected questions:

1. What regulated purpose does the system serve?
2. What is the boundary of the system and the validation effort?
3. Which failures could affect patient safety, data integrity or regulatory compliance?
4. What controls and assurance evidence will address those risks?
5. Who is responsible for producing, reviewing and approving that evidence?
6. How will the validated state be maintained after release?

The document should be proportionate. A system-specific plan for a heavily configured safety database may require detailed treatment of interfaces, migration, reporting rules, vendor evidence and regression strategy. A low-complexity regulated application may justify a much shorter plan if the same reasoning is still clear.

What the Validation Plan is not

The Validation Plan should not become a duplicate of every downstream validation record. Its purpose is to define the strategy, not to reproduce the User Requirements Specification, configuration design, executed test cases or validation report.

It is also not a declaration that software is universally “validated”. Validation is always connected to intended use and operating context. The same commercial product may be suitable for one use and inadequately assured for another, or may require different evidence where configuration, integrations or business processes differ.

Finally, the plan should not be treated as a document whose approval automatically establishes compliance. It is only useful if the strategy it describes is actually followed and if deviations from the strategy are controlled and justified.

Regulatory Framework and Status of the Validation Plan

A recurring source of confusion is the difference between the requirement to maintain an effective pharmacovigilance quality system and validate critical systems appropriately and the recommended practice of documenting the validation strategy in a named Validation Plan.

EU pharmacovigilance requirements

Commission Implementing Regulation (EU) No 520/2012 requires marketing authorisation holders, national competent authorities and EMA to establish and use an adequate and effective quality system for pharmacovigilance. The quality system covers organisational structure, responsibilities, procedures, processes, resources, compliance management and record management. It also requires quality-system elements to be documented systematically.

GVP Module I provides the principal operational guidance. Section I.B.8 states that facilities and equipment critical for the conduct of pharmacovigilance should undergo appropriate checks, qualification and/or validation activities to demonstrate suitability for their intended purpose. Computerised systems that materially support pharmacovigilance therefore fall within the quality-system framework.

GVP Module II makes the consequence visible in the Pharmacovigilance System Master File (PSMF). The PSMF should describe the location, functionality and operational responsibility of computerised systems and databases used to receive, collate, record and report safety information and should include an assessment of fitness for purpose. It should also summarise the validation status of key functionality and relevant controls such as change control, testing, backup arrangements and important electronic repositories.

These requirements establish the need for controlled, demonstrable fitness for purpose. They do not, however, prescribe a universal EU pharmacovigilance dossier format called a “Computerised System Validation Plan”. A system-specific Validation Plan is therefore best understood as a recommended operational control that helps the organisation organise and evidence how it will meet the applicable requirements.

EMA inspection interpretation for vendor systems

EMA’s pharmacovigilance inspection Q&A provides particularly useful interpretation for systems supplied or hosted by third parties. It states that the MAH remains ultimately responsible for validation of pharmacovigilance processes supported by electronic systems. The MAH may rely on qualification documentation produced by the vendor when that documentation has been assessed as adequate, but additional qualification or validation may still be needed on the basis of documented risk assessment.

For planning purposes, this means that a Validation Plan should not simply state that “the supplier validates the system”. It should explain which supplier evidence will be relied upon, how its adequacy will be assessed, what customer-specific configuration and operating differences exist, and what assurance remains the responsibility of the MAH.

Other frameworks: useful, but scope must remain clear

EU GMP Annex 11 and ISPE GAMP 5 contain mature principles for lifecycle management, supplier assessment, risk-based assurance, change control and periodic evaluation. They can provide useful structure for a pharmacovigilance validation programme. Their status must nevertheless be stated correctly: Annex 11 is part of the GMP framework and GAMP 5 is industry guidance. Neither should be converted into an invented EU pharmacovigilance legal requirement.

Similarly, FDA’s February 2026 guidance on Computer Software Assurance promotes a risk-based approach to confidence in software, but its formal scope is software used in medical-device production or medical-device quality management systems. Its assurance philosophy may be informative, but it is not a general FDA pharmacovigilance requirement.

The Validation Plan should therefore identify the actual regulatory basis that applies to the system and distinguish that basis from standards or guidance adopted voluntarily to structure the organisation’s approach.

Relationship to the Wider Validation Lifecycle

The Validation Plan sits near the beginning of the lifecycle but governs evidence generated across the lifecycle. Its logic can be expressed as a chain:

regulated process → intended use → applicable requirements → risks → controls → assurance evidence → release decision → lifecycle maintenance.

Each downstream validation activity should be traceable back to this logic. If testing is extensive but cannot be related to intended use or risk, the validation package may be large without being persuasive. Conversely, when the plan explains why particular evidence is sufficient, a proportionate assurance package can remain both efficient and defensible.

System-specific plan versus validation master plan

Organisations sometimes use the terms Validation Plan and Validation Master Plan interchangeably, but they often serve different levels of governance.

A validation master plan may describe organisation-wide principles: the lifecycle model, document hierarchy, risk methodology, approval conventions, supplier-assurance model and standard controls used across multiple systems. A system-specific Validation Plan applies those principles to one implementation or major project and records the decisions that are specific to that system.

The distinction is operational rather than regulatory. EU pharmacovigilance rules do not require those exact document titles. An organisation may combine or rename them provided the required controls and evidence remain clear, current and inspectable.

Building the Validation Plan

Once the regulatory context is clear, planning becomes an exercise in translating intended use into a proportionate assurance strategy. The sequence matters. Scope should not be defined from a list of available software features, and deliverables should not be selected merely because they appear in a corporate template. The plan should first establish the regulated use and the risks that arise from that use; only then should it define evidence and testing.

Define the intended use

The intended use should describe what the organisation relies on the system to do within the pharmacovigilance process. It should be specific enough to guide risk assessment and verification but not so detailed that it becomes a duplicate specification.

For a safety database, intended use may include receiving safety information, creating and maintaining case records, supporting medical review, applying configured workflows, calculating regulatory due dates, generating E2B messages, transmitting reports, recording acknowledgements and preserving the case history. For a signal-management platform, intended use may instead include importing defined data sets, calculating signal-detection outputs, supporting review decisions and maintaining an auditable decision trail.

The purpose of the intended-use statement is to establish the benchmark against which fitness for purpose will later be judged.

Define the system boundary

The plan should then explain what is considered part of the system for validation purposes. A useful boundary description may include:

• the principal application and configured modules;
• databases and data stores;
• interfaces and integration layers;
• reporting components;
• authentication or identity-management dependencies;
• relevant infrastructure or cloud services;
• regulated data migrations;
• externally hosted components;
• important manual controls that compensate for system limitations.

The boundary should be wide enough to include components that can materially affect the regulated process. A technically separate interface, for example, may still be part of the validation problem if it transforms or transmits safety data.

The plan should also state what is outside scope and why. Exclusions are useful only when they are justified. Declaring infrastructure, cybersecurity or a vendor-controlled component “out of scope” does not remove the need to understand dependencies that could affect intended use.

Identify supported pharmacovigilance processes

The plan should map the system to the pharmacovigilance processes it supports. Depending on the application, these may include case intake and processing, medical review, expedited reporting, reconciliation, literature monitoring, signal detection, aggregate reporting, risk-management activities, document control, training or quality management.

This process map helps distinguish technical criticality from pharmacovigilance criticality. A minor-looking function may be highly important if a regulated deadline or safety decision depends on it.

Applicable Requirements and Risk Strategy

Validation planning should identify the requirements that actually apply to the system and the method used to decide where assurance effort should be concentrated.

Separate regulatory requirements from organisational standards

A clear plan should distinguish at least three layers:

1. directly applicable legal or regulatory requirements, such as EU pharmacovigilance quality-system obligations and relevant electronic-record requirements;
2. regulatory guidance and interpretation, such as GVP and EMA inspection Q&As; and
3. organisational or industry methods, such as internal validation procedures, GAMP-based lifecycle models or selected data-integrity frameworks.

This distinction prevents internal conventions from being presented as if regulators prescribed them. For example, an organisation may choose to use a traditional URS–FS–DS–IQ–OQ–PQ document set, but EU pharmacovigilance law does not mandate that exact sequence for every PV system.

Define how risk will influence validation

The plan should describe the risk methodology before test scope is finalised. The method need not depend on a particular numerical matrix, but it should explain how the organisation will consider consequences of failure and the effectiveness of existing controls.

Risk assessment should connect a potential failure to its regulated consequence. Relevant questions include:

• Could the failure affect patient safety or a safety decision?
• Could it cause loss, corruption or misinterpretation of regulated data?
• Could it lead to late, missing or incorrect regulatory reporting?
• Could it prevent reconstruction of a regulated action or decision?
• How likely is the failure to be detected before it affects the process?
• Which preventive or detective controls already exist?
• What additional assurance is justified by the residual risk?

The purpose is not to produce a score for its own sake. The output should influence what is tested, how rigorously it is tested, what supplier evidence can be reused and what controls require lifecycle monitoring.

Identify critical functions and records

The plan should define how criticality will be determined. In a pharmacovigilance setting, examples of potentially high-impact functions include regulatory due-date calculation, E2B message generation, submission routing, acknowledgement reconciliation, access control, audit trails, duplicate management, safety-data transformation and signal-data imports.

These examples are not a universal classification. Criticality depends on intended use, local configuration and compensating controls. The plan should therefore record the reasoning rather than rely on a generic list copied from another implementation.

Roles, Responsibilities and Decision Rights

Validation work is multidisciplinary. The plan should describe not merely who performs tasks, but who has authority to make the important validation decisions.

Pharmacovigilance process owner

The PV process owner should define the regulated business need, identify critical process requirements, participate in risk assessment, review relevant evidence and judge whether the implemented system supports the intended use. This responsibility cannot be replaced by purely technical sign-off.

System owner and information technology

The system owner or IT function may be responsible for architecture, infrastructure, environments, deployment, technical monitoring, interfaces, backup, restoration, security implementation and technical change. The plan should make clear which evidence comes from these functions and how it supports the regulated process.

Quality function

Quality commonly governs the validation procedure, reviews compliance with the agreed strategy, provides independent challenge where required and ensures that deviations and residual risks are handled consistently. The exact approval model should be stated rather than assumed.

Supplier or service provider

The supplier may provide software-development evidence, qualification records, release documentation, testing, hosting, infrastructure controls and technical support. The plan should distinguish supplier responsibility for producing evidence from MAH responsibility for deciding whether that evidence is adequate for the intended PV use.

QPPV oversight

The EU QPPV is not automatically the approver of every validation record. The plan should align QPPV involvement with the governance model and the materiality of the system to the pharmacovigilance system. For critical systems, the QPPV should have access to information on significant risks, incidents, compliance impacts and controls sufficient to exercise appropriate oversight.

A simple responsibility table can make this clearer:

This table is an illustrative operating model, not a regulatory assignment of named roles.

Supplier Reliance and Outsourced Systems

Supplier-managed and SaaS systems require especially clear validation planning because evidence and operational control are distributed across organisations.

Decide what supplier evidence can be relied upon

EMA’s pharmacovigilance inspection Q&A allows an MAH to rely on vendor qualification documentation when the vendor’s activities and documentation have been adequately assessed. The plan should therefore state how supplier assurance will be established, for example through audit or another sufficiently robust assessment, and which evidence is expected to remain accessible for inspection.

The assessment should consider whether the supplier’s validation environment, configuration, release process and controls are sufficiently representative of the MAH’s production use. Where differences are material, customer-specific assurance may be required.

Identify the customer-specific assurance gap

Even strong supplier evidence usually does not establish fitness for every customer implementation. The Validation Plan should identify customer-specific elements such as:

• local or global configuration;
• interfaces;
• migrated data;
• reporting rules;
• user roles and access design;
• business procedures;
• local workarounds;
• integrations with regulatory gateways or partners;
• trained-user dependent performance.

The validation strategy should then explain how those elements will be verified.

Plan for ongoing supplier change

For SaaS systems, supplier releases may occur frequently. The plan should define how release information will be obtained, how relevance will be assessed, when customer testing is required, how unresolved issues are escalated and how the validation record is updated. Initial supplier qualification is not enough if later changes can alter regulated behaviour.

Validation Deliverables and Evidence Architecture

Once scope, risk and responsibilities have been defined, the plan should explain what evidence will be generated and how the evidence will fit together. The emphasis should be on the purpose of each record, not on reproducing a fixed historical document set.

Avoid turning document names into requirements

Many organisations use familiar deliverables such as a User Requirements Specification (URS), Functional Specification (FS), Design or Configuration Specification, risk assessment, traceability matrix, Installation Qualification (IQ), Operational Qualification (OQ), Performance Qualification (PQ), User Acceptance Testing (UAT) and Validation Summary Report. These can be useful, but they are not a universal EU pharmacovigilance-mandated sequence.

A modern Validation Plan should therefore define the records needed to establish the assurance argument and explain where equivalent evidence is combined, reused or produced by a supplier. For a configurable SaaS platform, for example, infrastructure qualification may be largely supplier-managed while the MAH concentrates on intended use, configuration, interfaces, critical workflows and regulated data. For a bespoke integration, technical design and interface verification may require substantially more local evidence.

A practical evidence architecture may include:

This table is a recommended planning model. An organisation may use different document names or combine evidence where the resulting record remains controlled, understandable and traceable.

Define document and evidence ownership

The plan should state who authors, reviews, approves and retains each important category of evidence. Where supplier documents are relied upon, it should also define where those documents are held, how they can be accessed, and how the organisation ensures that the version reviewed remains identifiable.

This matters during inspection. A reference to “vendor validation documentation” is weak if the MAH cannot identify the relevant evidence, explain its content or retrieve it promptly.

Verification and Testing Strategy

The testing section of the Validation Plan should explain how confidence will be generated, not simply list protocol names.

Link testing to risk and intended use

High-impact functions should receive assurance proportionate to the consequence and detectability of failure. Testing should cover the behaviour that matters to the PV process, including relevant positive, negative, boundary and exception conditions.

For a regulatory reporting function, useful scenarios may include correct identification of reportability, due-date calculation, message generation, transmission, rejection handling and acknowledgement reconciliation. For a signal-data interface, assurance may instead focus on completeness, transformation rules, terminology/version handling, failure detection and reconciliation.

The plan should describe the logic for selecting scenarios. It need not contain the detailed scripts themselves.

Scripted and unscripted assurance

Traditional validation often relies heavily on pre-scripted tests. Those remain useful where precise repeatability and objective expected results are important, but not every function requires the same testing method.

The plan may allow a combination of scripted testing, exploratory testing, automated checks, supplier evidence, inspection of configuration, code or design review where applicable, data reconciliation and other assurance activities. The chosen method should be appropriate to the risk and should produce evidence sufficient to reconstruct what was evaluated and what conclusion was reached.

This risk-based flexibility is an implementation approach. It should not be represented as permission to omit evidence for high-impact functions.

Define acceptance criteria before execution

The plan should explain what must be true before the system can be released for regulated use. Acceptance criteria may address:

• completion of planned critical assurance activities;
• resolution or formal risk acceptance of significant deviations;
• approved configuration and requirements;
• satisfactory migration and reconciliation where applicable;
• availability of required procedures and support arrangements;
• completion of required training;
• establishment of access, backup, continuity and incident controls;
• confirmation that residual risks are acceptable to the designated decision-makers.

Acceptance criteria should be defined before the result is known. Retrospective criteria weaken the independence of the release decision.

Deviations, Defects and Traceability

Unexpected results are normal in complex implementations. The Validation Plan should therefore explain how deviations and defects will be classified, investigated and resolved, and who has authority to accept residual risk.

Distinguish test failure from business impact

A failed test does not automatically mean the system is unsuitable, and a passed test does not automatically mean the regulated process is protected. The investigation should consider what failed, why it failed, whether other functions or data are affected, whether a workaround exists and whether the residual risk is acceptable.

Where a defect remains open at release, the justification should be explicit. The plan should prevent significant unresolved issues from disappearing into a generic defect backlog without a regulated-use decision.

Build traceability around the assurance argument

Traceability demonstrates the relationship among intended use, requirements, risks, controls and evidence. A conventional traceability matrix is one way to achieve this, but the underlying requirement is conceptual: the organisation should be able to show which critical requirements were addressed, what risks they relate to, what evidence supports them and whether any exceptions remain.

For large systems, traceability also helps future change assessment. When a reporting rule changes, the organisation can identify the affected requirements, tests and controls rather than retesting unrelated functionality.

Data Migration and Interfaces

Data migration and interfaces deserve explicit treatment because they can preserve technical connectivity while changing the meaning or completeness of safety information.

Migration planning

Where regulated records are migrated, the plan should define the migration scope, source and target, transformation rules, reconciliation method, handling of rejected or exceptional records, acceptance criteria and responsibilities. The strategy should consider not only record counts but whether important fields, histories, attachments, audit information and relationships remain usable for the intended PV purpose.

A migration may require staged or sampled verification depending on scale and risk. The plan should explain why the selected approach provides adequate confidence.

Interface assurance

Interfaces should be assessed end to end. A message leaving one application successfully does not prove that the receiving application interpreted it correctly. The plan should therefore address mapping, transformation, transport, error handling, reprocessing, acknowledgements, reconciliation and monitoring where those elements affect regulated data or reporting.

Maintaining the Validated State

The Validation Plan should not end at go-live. It should define how the assurance established during implementation will be maintained as the system changes.

Change control

The plan should describe how proposed changes will be assessed for effect on intended use, regulated data, critical functionality, interfaces, security and existing evidence. It should define how the organisation determines the need for additional or regression testing and how documentation is updated.

Not every change requires the same degree of revalidation. The objective is to preserve the validation argument by understanding what the change affects and what evidence remains valid.

Incident and problem management

Operational incidents should be assessed for both technical impact and pharmacovigilance impact. A restored service may still leave late cases, missing submissions, corrupted records or incomplete analyses that require PV investigation.

The plan should therefore identify the interface between technical incident management and regulated deviation/CAPA processes where appropriate.

Periodic review

The plan should explain how continued fitness for purpose will be reassessed. EU GVP does not prescribe a universal annual CSV review interval for every PV system. Review frequency and depth should be justified by the organisation’s procedure and the system’s risk and change profile.

Relevant evidence may include significant changes, incidents, recurring defects, access reviews, supplier performance, backup/restoration results, business-continuity exercises, outstanding CAPAs, regulatory changes and the current validation status.

Retirement

Retirement should be planned before the system disappears from operational use. The Validation Plan or linked lifecycle procedure should identify how regulated records will be retained, migrated or archived; how historical data will remain accessible and interpretable; how interfaces and access will be decommissioned; and how the retirement decision will be documented.

The validated state therefore has an endpoint, but regulatory responsibility for the records may continue beyond system retirement.

Practical Structure of a System-Specific Validation Plan

A useful Validation Plan should be easy for a project team, reviewer or inspector to follow. The exact headings are not prescribed by EU pharmacovigilance legislation, but a coherent system-specific plan commonly addresses the following subjects in a logical sequence.

1. Document purpose and applicability

State why the plan exists, which system or implementation it governs, which organisational procedure or validation framework it applies, and whether it covers a new implementation, major upgrade, migration, replacement or other defined scope.

2. System and process description

Describe the system at a level sufficient to understand the regulated context. Identify the principal PV processes supported, relevant users, important locations or hosting arrangements, interfaces and major dependencies.

3. Intended use

Define what the organisation relies on the system to do. This statement should be stable enough to guide requirements, risk assessment and release decisions while remaining specific to the actual PV process.

4. Scope and exclusions

Define the system boundary, modules, environments, interfaces, data, migration activities and organisational units covered by the plan. Explain meaningful exclusions rather than listing them without justification.

5. Regulatory and procedural basis

Identify directly applicable requirements, relevant regulatory guidance and organisational procedures. Distinguish mandatory requirements from voluntarily adopted standards or industry frameworks.

6. Risk-management strategy

Explain how critical functions, records and failure modes will be identified and how risk will influence supplier reliance, testing depth, review and acceptance decisions. State the methodology or controlled procedure used.

7. Supplier and service-provider strategy

Describe what evidence will come from the supplier, how the supplier and its qualification activities will be assessed, which responsibilities remain with the MAH and how relevant evidence will remain accessible.

8. Validation deliverables and evidence

List the planned evidence by purpose rather than assuming that every project needs the same document names. Identify ownership, review and approval responsibilities and explain where records will be combined or reused.

9. Verification and testing strategy

Describe how critical requirements and risks will be verified, the types of testing or assurance methods allowed, test environments, data requirements, acceptance criteria and handling of deviations.

10. Data migration and interfaces

Where applicable, define the approach to migration, reconciliation, transformation, interface testing, exception handling and end-to-end verification.

11. Training and operational readiness

State the conditions that must exist before regulated use, including relevant procedures, trained users, support arrangements, access controls, continuity measures and operational ownership.

12. Release and acceptance

Define who decides that the system is fit for intended use and what evidence must be complete before that decision. Describe how residual risks and open issues are handled.

13. Lifecycle maintenance

Explain how changes, supplier releases, incidents, periodic review, backup/restoration, business continuity and retirement will be governed after release.

14. Deviations from the plan

Define how departures from the approved strategy are documented, assessed and approved. A validation plan should control the strategy without becoming so rigid that justified changes cannot be made.

This structure is a recommended operating model, not a prescribed regulatory template.

Illustrative Example: Planning Validation of a Global Safety Database Upgrade

Consider a hypothetical MAH upgrading a global safety database used for case processing and E2B(R3) reporting. The supplier hosts the application as SaaS and provides release qualification documentation.

The Validation Plan would first define the regulated use: case intake, workflow, medical review, reporting-rule calculation, electronic submission, acknowledgement handling and maintenance of the case history. It would then identify the implementation boundary, including the hosted application, configured reporting rules, regulatory gateway interface, partner interfaces, identity management and downstream reporting feed.

The supplier’s qualification package could be identified as an important evidence source, but the plan would also define customer-specific assurance for configured reporting rules, interfaces, user roles, migrated or transformed data and end-to-end regulatory reporting. Risk assessment might identify due-date calculation, E2B transformation, submission routing and acknowledgement reconciliation as functions requiring greater assurance than cosmetic interface changes.

The test strategy could then specify representative positive, negative and exception scenarios, while acceptance criteria would require resolution or formal risk acceptance of significant deviations, successful end-to-end reporting, completed procedural updates, trained users and approved operational controls.

Finally, the plan would describe how future SaaS releases will be assessed and how incidents that affect submissions will be linked to PV impact assessment. The result is not simply a list of documents. It is a reasoned explanation of how confidence in the upgraded system will be established and maintained.

Special Situations

Some implementations require additional planning because the traditional boundary between software, organisation and evidence is less clear.

Cloud and SaaS systems

Cloud hosting does not remove the need to understand infrastructure dependencies, but it changes how assurance may be obtained. The plan should identify which controls are performed by the provider, which evidence is available, how provider changes are communicated and what the MAH must verify locally.

The organisation should avoid claiming that cloud infrastructure is “out of scope” when availability, security, backup or configuration can affect regulated use. A better approach is to define which controls are supplier-managed and how their adequacy is assessed.

Global systems with local processes

A global validation package may cover common application functionality while local affiliates rely on additional configuration, interfaces or procedures. The plan should identify which elements are globally assured and which require local assessment or evidence.

Local validation should not duplicate global evidence unnecessarily, but global validation should not be assumed to cover materially different local use.

Artificial intelligence and adaptive functions

Where a system includes artificial-intelligence or machine-learning functionality, the plan should begin by defining exactly how that functionality is used in the PV process. The assurance problem differs substantially between a tool that suggests duplicate cases for human review and one whose output directly changes regulated data or drives automated decisions.

The plan should consider model or algorithm versioning, input-data quality, performance characteristics, human oversight, change mechanisms, monitoring and the possibility that output behaviour may vary over time. Existing pharmacovigilance obligations continue to apply; the presence of AI does not create an exemption from fitness-for-purpose, data-integrity or governance expectations.

No general EU pharmacovigilance rule currently prescribes a single validation method for all AI-enabled PV systems. The validation strategy should therefore be risk-based, technology-aware and explicit about uncertainty and human controls.

Potential Failure Modes

The following are illustrative failure modes rather than cited inspection findings.

The plan is written after testing has already been decided

If the Validation Plan is approved only after protocols and scripts are complete, it cannot genuinely direct the validation strategy. It becomes retrospective documentation rather than planning.

The document set is copied from another system

A template may be efficient, but copied deliverables can produce unnecessary testing for low-risk functions while overlooking interfaces or configurations that are critical to the actual PV use.

Intended use is too vague

Statements such as “the system supports pharmacovigilance” do not define what must be assured. Without a specific intended-use statement, risk assessment and testing can drift toward generic software functionality.

Supplier validation is treated as customer validation

Supplier evidence may be robust while still failing to address organisation-specific configuration, data, interfaces and workflows. The plan should explicitly define the boundary of reliance.

Acceptance criteria are defined retrospectively

If release criteria are adjusted after failures are known, the release decision becomes vulnerable to confirmation bias. Significant deviations should instead be assessed through a controlled residual-risk process.

Lifecycle controls are omitted

A plan that ends at go-live may produce a strong initial package but weak control over later releases, configuration changes and incidents. The validated state is maintained through lifecycle governance, not by preserving an old validation report.

Every change triggers the same revalidation package

This usually indicates that risk assessment is not functioning as intended. Change impact should determine which requirements, controls and evidence are affected.

Inspection Considerations

An inspector is unlikely to judge a Validation Plan only by its formatting. The more important question is whether the document accurately predicts and explains the validation evidence that exists.

Potential inspection questions include:

• What is the intended use of this system within the pharmacovigilance process?
• Why was this validation strategy selected?
• Which functions were considered critical, and how did that affect testing?
• Which regulatory requirements apply directly to the system?
• Which supplier evidence was relied upon, and how was its adequacy assessed?
• How do customer configuration and production conditions differ from the supplier’s qualification environment?
• How are requirements, risks and evidence traceable?
• How were migration and interfaces verified?
• What significant deviations remained at release, and who accepted the residual risk?
• How is the validation strategy adapted for subsequent supplier releases and internal changes?
• How does the PSMF reflect the system and its validation status?
• Can the organisation retrieve the supplier and internal validation evidence promptly?

The plan is strongest when those questions can be answered directly from the document and then confirmed by the underlying records.

Practical Review Checklist

Before approving a system-specific Validation Plan, the reviewer should be able to confirm that:

• the intended PV use is clear and specific;
• the system boundary and important dependencies are understood;
• regulated processes supported by the system are identified;
• applicable legal requirements, regulatory guidance and internal standards are distinguished;
• risk assessment will influence assurance effort before testing is finalised;
• critical functions and records will be identified using defined reasoning;
• roles and decision rights are explicit;
• supplier reliance is justified and customer-specific assurance gaps are addressed;
• validation deliverables are selected for their evidentiary purpose rather than copied mechanically;
• testing methods are proportionate to risk and linked to intended use;
• migration and interfaces are addressed where relevant;
• acceptance criteria are defined before execution;
• deviations and residual risks have a controlled decision process;
• release responsibilities are explicit;
• operational readiness, training and support requirements are included;
• change, incident, periodic review and retirement controls are defined;
• deviations from the approved validation strategy can be documented and approved;
• the document is consistent with the organisation’s PSMF and related quality-system records.

Key Takeaways

A Computerised System Validation Plan is best understood as the strategy document for the validation argument. It explains how an organisation will establish and maintain confidence that a computerised system is fit for its intended pharmacovigilance use.

EU pharmacovigilance rules require an adequate quality system and appropriate validation or qualification of critical facilities and equipment, and the PSMF must describe relevant computerised systems, fitness for purpose and validation status. Those requirements do not prescribe a universal document entitled “CSV Plan”. The Validation Plan is therefore a recommended governance mechanism for implementing and evidencing those obligations coherently.

The plan should be driven by intended use and risk rather than by a fixed list of document names. Supplier evidence can reduce duplication, particularly for commercial or SaaS systems, but the MAH remains responsible for understanding the adequacy of that evidence and for assuring its own configuration, interfaces, data and regulated processes.

A strong Validation Plan also extends beyond initial release. It establishes how changes, supplier releases, incidents, periodic review and retirement will preserve the validation argument over time. Its quality can ultimately be judged by a simple test: does the document make it possible to understand why the planned evidence will be sufficient to conclude that this system is fit for this pharmacovigilance purpose?

References

1. European Commission. Commission Implementing Regulation (EU) No 520/2012 on the performance of pharmacovigilance activities, consolidated version current at 12 February 2026. EUR-Lex. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02012R0520-20260212
2. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module I – Pharmacovigilance systems and their quality systems. EMA/541760/2011. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-i-pharmacovigilance-systems-and-their-quality-systems_en.pdf
3. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module II – Pharmacovigilance system master file (Rev. 2). EMA/816573/2011 Rev. 2. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-ii-pharmacovigilance-system-master-file-rev-2_en.pdf
4. European Medicines Agency. Coordination of pharmacovigilance inspections — Human Pharmacovigilance inspections Q&A on validation/qualification of vendor electronic systems. https://www.ema.europa.eu/en/coordination-pharmacovigilance-inspections-0
5. European Commission. EudraLex Volume 4, Annex 11: Computerised Systems. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
6. U.S. Food and Drug Administration. Part 11, Electronic Records; Electronic Signatures — Scope and Application. Guidance for Industry, September 2003. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application
7. U.S. Food and Drug Administration. Computer Software Assurance for Production and Quality Management System Software. Guidance for Industry and FDA Staff, February 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/computer-software-assurance-production-and-quality-management-system-software
8. International Society for Pharmaceutical Engineering. GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems, Second Edition. ISPE, 2022. Industry guidance; not legislation.

Regulatory Note

This article distinguishes binding requirements, regulatory guidance and recommended operational practice. Commission Implementing Regulation (EU) No 520/2012 is legally binding within its scope. EMA GVP Modules I and II provide the principal EU pharmacovigilance guidance discussed here, and EMA’s pharmacovigilance inspection Q&A provides regulatory interpretation concerning vendor-supported electronic systems. EU GMP Annex 11 is a GMP document and is referenced only for relevant computerised-system principles; it should not be interpreted as imposing GMP requirements automatically on a system used solely for pharmacovigilance. FDA guidance documents describe the Agency’s current thinking and are non-binding unless specific statutory or regulatory provisions apply. FDA’s February 2026 Computer Software Assurance guidance is formally scoped to medical-device production and quality-management-system software. ISPE GAMP 5 is industry guidance. A document specifically titled “Computerised System Validation Plan” is not prescribed as a universal EU pharmacovigilance legal requirement; it is presented here as a recommended method for organising and evidencing a compliant, risk-proportionate validation strategy.